Projekt
A phase III, open-label, randomized study of MPDL3280A (AntiPD-L1 antibody) in combination with carboplatin Paclitaxel with or without bevacizumab compared with carboplatin Paclitaxel bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer
Automatisch geschlossen · 2016 bis 2020
Früh Martin